Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Correspondence: David B. Weiner, Department of Pathology and Laboratory Medicine, University of Pennsylvania, 505 Stellar-Chance Lab., 422 Curie Dr., Philadelphia, PA 19104. E-mail: dbweiner{at}mail.med.upenn.edu
DNA vaccination, or genetic immunization, is a novel vaccine technology that has great potential for reducing infectious disease and cancer-induced morbidity and mortality worldwide. Since their inception, DNA vaccines have been used to stimulate protective immunity against many infectious pathogens, malignancies, and autoimmune disorders in animal models. Plasmid DNA encoding a polypeptide protein antigen is introduced into a host where it enters host cells and serves as an epigenetic template for the high-efficiency translation of its antigen. An immune response, which is mediated by the cellular and/or humoral arms of the immune system and is specific for the plasmid-encoded antigen, ensues. It is thought that "professional" antigen-presenting cells play a dominant role in the induction of immunity by presenting vaccine peptides on MHC class I molecules, following direct transfection or "cross"-presentation, and MHC class II molecules after antigen capture and processing within the endocytic pathway. The correlates of immunity can be manipulated according to many immunization parameters, including the method of vaccine delivery, presence of genetic adjuvants, and vaccine regimen. DNA vaccines first advanced to the clinic five years ago, and the initial picture of their utility in humans is emerging. However, further analysis is required to determine their ultimate efficacy and safety in human beings. This technology has acquired a strong foothold in the field of experimental immunotherapy, and it is hoped that it will eventually represent the next generation of prophylactic and therapeutic vaccines.
Key Words: DNA vaccines • genetic immunization • genetic vaccination • immunotherapy • DNA plasmid • cross-presentation • cross-priming • genetic adjuvant • prime-boost
This article has been cited by other articles:
 |
|
 |
|
  Y. S. Park, J. H. Lee, C.-F. Hung, T.-C. Wu, and T. W. Kim Enhancement of Antibody Responses to Bacillus anthracis Protective Antigen Domain IV by Use of Calreticulin as a Chimeric Molecular Adjuvant Infect. Immun., May 1, 2008; 76(5): 1952 - 1959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Boyer, T. M. Robinson, M. A. Kutzler, G. Vansant, D. A. Hokey, S. Kumar, R. Parkinson, L. Wu, M. K. Sidhu, G. N. Pavlakis, et al. Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid PNAS, November 20, 2007; 104(47): 18648 - 18653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Peng, C. Trimble, L. Wu, D. Pardoll, R. Roden, C.-F. Hung, and T.-C. Wu HLA-DQB1*02-Restricted HPV-16 E7 Peptide-Specific CD4+ T-Cell Immune Responses Correlate with Regression of HPV-16-Associated High-Grade Squamous Intraepithelial Lesions Clin. Cancer Res., April 15, 2007; 13(8): 2479 - 2487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. de Gruijl, O. J. A. E. Ophorst, J. Goudsmit, S. Verhaagh, S. M. Lougheed, K. Radosevic, M. J. E. Havenga, and R. J. Scheper Intradermal Delivery of Adenoviral Type-35 Vectors Leads to High Efficiency Transduction of Mature, CD8+ T Cell-Stimulating Skin-Emigrated Dendritic Cells J. Immunol., August 15, 2006; 177(4): 2208 - 2215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Report of the American Animal Hospital Association, M. A. Paul, L. E. Carmichael, H. Childers, S. Cotter, A. Davidson, R. Ford, K. F. Hurley, J. A. Roth, R. D. Schultz, et al. 2006 AAHA Canine Vaccine Guidelines J. Am. Anim. Hosp. Assoc., March 1, 2006; 42(2): 80 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Peng, H. Ji, C. Trimble, L. He, Y.-C. Tsai, J. Yeatermeyer, D. A. K. Boyd, C.-F. Hung, and T.-C. Wu Development of a DNA Vaccine Targeting Human Papillomavirus Type 16 Oncoprotein E6 J. Virol., August 15, 2004; 78(16): 8468 - 8476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Shen and K. L. Rock Cellular protein is the source of cross-priming antigen in vivo PNAS, March 2, 2004; 101(9): 3035 - 3040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H. Day, Y. Zhang, P. Clair, K. H. Grabstein, M. Mazel, A. R. Rees, M. Kaczorek, and J. Temsamani Induction of Antigen-Specific CTL Responses Using Antigens Conjugated to Short Peptide Vectors J. Immunol., February 1, 2003; 170(3): 1498 - 1503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. D. Davis, M. Jefford, P. Parente, and J. Cebon Rational approaches to human cancer immunotherapy J. Leukoc. Biol., January 1, 2003; 73(1): 3 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Coban, K. J. Ishii, D. J. Sullivan, and N. Kumar Purified Malaria Pigment (Hemozoin) Enhances Dendritic Cell Maturation and Modulates the Isotype of Antibodies Induced by a DNA Vaccine Infect. Immun., July 1, 2002; 70(7): 3939 - 3943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Campos-Neto, J. R. Webb, K. Greeson, R. N. Coler, Y. A. W. Skeiky, and S. G. Reed Vaccination with Plasmid DNA Encoding TSA/LmSTI1 Leishmanial Fusion Proteins Confers Protection against Leishmania major Infection in Susceptible BALB/c Mice Infect. Immun., June 1, 2002; 70(6): 2828 - 2836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-F. Hung, L. He, J. Juang, T.-J. Lin, M. Ling, and T.-C. Wu Improving DNA Vaccine Potency by Linking Marek's Disease Virus Type 1 VP22 to an Antigen J. Virol., February 22, 2002; 76(6): 2676 - 2682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Lipscomb and B. J. Masten Dendritic Cells: Immune Regulators in Health and Disease Physiol Rev, January 1, 2002; 82(1): 97 - 130. [Abstract] [Full Text] [PDF]
|
|
